{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:09Z","timestamp":1791235089405,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005205","name":"J&J Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.thromres.2025.109564","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:05:16Z","timestamp":1765641916000},"page":"109564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The in vitro anticoagulant effect of milvexian in healthy neonates and children"],"prefix":"10.1016","volume":"257","author":[{"given":"Natasha","family":"Letunica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Karlaftis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.thromres.2025.109564_bb0005","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00228-020-02856-6","article-title":"Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication","volume":"76","author":"Rydberg","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.thromres.2025.109564_bb0010","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2025.109564_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323137","article-title":"Anticoagulant prescribing trends, bleeding events, and reversal agent use in pediatric patients: a retrospective, real-world study","volume":"20","author":"D\u2019Abrantes","year":"2025","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.thromres.2025.109564_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.amj.2016.01.001","article-title":"Emergent bleeding in patients receiving direct oral anticoagulants","volume":"35","author":"Summers","year":"2016","journal-title":"Air Med. J."},{"key":"10.1016\/j.thromres.2025.109564_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.684638","article-title":"Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice","volume":"12","author":"Roberti","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109564_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100140","article-title":"What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?","volume":"7","author":"Betensky","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"issue":"24","key":"10.1016\/j.thromres.2025.109564_bb0035","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109564_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100094","article-title":"Physical activity for children with deep vein thrombosis and pulmonary embolism on anticoagulation: a scoping review","volume":"7","author":"Bastas","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"issue":"Supplement 1","key":"10.1016\/j.thromres.2025.109564_bb0045","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2023-186089","article-title":"Heavy menstrual bleeding in adolescents on direct oral anticoagulants","volume":"142","author":"Datta","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2025.109564_bb0050","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2025.109564_bb0055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2025.109564_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.thromres.2025.109564_bb0065","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/jth.12372","article-title":"Developmental hemostasis: age-specific differences in the levels of hemostatic proteins","volume":"11","author":"Attard","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109564_bb0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis: impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109564_bb0075","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.thromres.2012.07.009","article-title":"The in vitro anticoagulant effect of rivaroxaban in children","volume":"130","author":"Attard","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109564_bb0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.thromres.2020.05.020","article-title":"Age-specific differences in the in vitro anticoagulant effect of Bivalirudin in healthy neonates and children compared to adults","volume":"192","author":"Letunica","year":"2020","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2025.109564_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MBC.0000000000000033","article-title":"The in-vitro anticoagulant effect of rivaroxaban in neonates","volume":"25","author":"Attard","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"6","key":"10.1016\/j.thromres.2025.109564_bb0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.thromres.2005.11.004","article-title":"Age-related differences in heparin response","volume":"118","author":"Ignjatovic","year":"2006","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2025.109564_bb0095","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2010.08163.x","article-title":"Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children","volume":"149","author":"Ignjatovic","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109564_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025897","article-title":"A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology: the HAPPI Kids study protocol","volume":"9","author":"Hoq","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.thromres.2025.109564_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109564_bb0110","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S488414","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of milvexian in healthy Chinese adults","volume":"19","author":"Luo","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"Supplement_2","key":"10.1016\/j.thromres.2025.109564_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.3068","article-title":"Differential impact of milvexian, an investigational oral FXIa inhibitor vs apixaban and dabigatran on thrombin generation in human donor plasma in vitro","volume":"43","author":"Bunce","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2025.109564_bb0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.thromres.2025.109564_bb0125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.thromres.2008.02.001","article-title":"The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults","volume":"122","author":"Ignjatovic","year":"2008","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2025.109564_bb0130","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.thromres.2015.10.034","article-title":"Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults","volume":"136","author":"Ignjatovic","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109564_bb0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","article-title":"A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study","volume":"217","author":"Payne","year":"2019","journal-title":"Am. Heart J."},{"issue":"22","key":"10.1016\/j.thromres.2025.109564_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.thromres.2025.109564_bb0145","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109564_bb0150","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109564_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1477-9560-3-16","article-title":"Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay","volume":"3","author":"Gerotziafas","year":"2005","journal-title":"Thromb. J."},{"issue":"4","key":"10.1016\/j.thromres.2025.109564_bb0160","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1160\/TH09-10-0687","article-title":"The in vitro response to low-molecular-weight heparin is not age-dependent in children","volume":"103","author":"Ignjatovic","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109564_bb0165","first-page":"712","article-title":"Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators","volume":"48","author":"Lim","year":"2016","journal-title":"Pathology (Phila.)"},{"issue":"2 Suppl","key":"10.1016\/j.thromres.2025.109564_bb0170","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109564_bb0175","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/eurheartjsupp\/suae013","article-title":"Factor XI inhibition in patients with acute coronary syndrome","volume":"26","author":"Raffo","year":"2024","journal-title":"Eur Heart J Suppl J Eur Soc Cardiol."},{"key":"10.1016\/j.thromres.2025.109564_bb0180","article-title":"Milvexian: a focus on a new oral anticoagulant that targets factor XIa for thromboembolism prophylaxis","author":"Birchansky","year":"2024","journal-title":"Cardiol. Rev."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825003147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825003147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:26:22Z","timestamp":1768386382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825003147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0049384825003147"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109564","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in vitro anticoagulant effect of milvexian in healthy neonates and children","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109564"}}